Recognizing the cyclical nature of the lending business, it becomes crucial to address potential risks during favourable periods when banks have the capacity to absorb the impact of new norms.
UBS sells shares worth Rs 480 crore in Concord Biotech, IIFL Securities, 2 more stocks via block deals
UBS sold holdings in Concord Biotech, Five Star Business Finance, IIFL Securities, and Marksans Pharma through block deals, totaling Rs 480 crore. The largest sale